Your patient is bleeding or needs urgent surgery, but no one knows when the last DOAC dose was taken. Is there still enough factor Xa inhibitor on board to change what happens next?

Join experts Alex Spyropoulos, Christopher Baugh, and Deborah Siegal as they discuss:

• Why stabilization must come before laboratory confirmation

• The limitations of routine coagulation tests

• How to interpret drug-specific and heparin-calibrated anti-Xa assays

• Practical pathways for major bleeding and urgent surgery

• The future of rapid point-of-care testing

Tune in now and subscribe to Clot, Clot, Who’s There? for more expert conversations in thrombosis, hemostasis, and vascular medicine.

00:00: Assessing Residual Factor Xa Activity

03:41: Stabilize First, Test Second

08:56: Lab Testing: Options and Limitations

18:20: Major Bleeding vs. Urgent Surgery

21:54: The Future of Point-of-Care Testing

Thank you to our sponsor, VarmX, for their generous support of this podcast episode. 

Check out the companion learning course, No Time To Wait: Urgent Situations in Patients on Factor Xa Inhibitors, here.